Clover Biopharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Joshua G. Liang
Chief executive officer
CN¥17.4m
Total compensation
| CEO salary percentage | 25.2% |
| CEO tenure | 4yrs |
| CEO ownership | 1.6% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥884m |
| Mar 31 2024 | n/a | n/a | -CN¥511m |
| Dec 31 2023 | CN¥17m | CN¥4m | -CN¥139m |
| Sep 30 2023 | n/a | n/a | -CN¥402m |
| Jun 30 2023 | n/a | n/a | -CN¥665m |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥30m | CN¥8m | -CN¥2b |
| Sep 30 2022 | n/a | n/a | -CN¥4b |
| Jun 30 2022 | n/a | n/a | -CN¥6b |
| Mar 31 2022 | n/a | n/a | -CN¥6b |
| Dec 31 2021 | CN¥15m | CN¥8m | -CN¥6b |
| Dec 31 2020 | CN¥4m | CN¥4m | -CN¥913m |
Compensation vs Market: Joshua G.'s total compensation ($USD2.38M) is above average for companies of similar size in the Hong Kong market ($USD230.70K).
Compensation vs Earnings: Joshua G.'s compensation has been consistent with company performance over the past year.
CEO
Joshua G. Liang (31 yo)
4yrs
Tenure
CN¥17,390,000
Compensation
Mr. Joshua G. Liang is Executive Director and Chief Executive Officer at Clover Biopharmaceuticals, Ltd. since December 25, 2020. Mr. Liang is primarily responsible for leading the management and operation...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.2yrs | CN¥5.83m | 16.18% HK$ 52.5m | |
| CEO & Executive Director | 4yrs | CN¥17.39m | 1.6% HK$ 5.2m | |
| Chief Technology Officer | 1.9yrs | no data | no data | |
| Chief Medical Officer of Vaccine | 3.8yrs | no data | no data | |
| Chief Technical Operation Officer | no data | no data | no data | |
| Senior Vice President of Corporate Strategy & Business Development | 3yrs | no data | no data | |
| Senior Vice President of Head of Regulatory Affairs | 3yrs | no data | no data | |
| President of Global Research & Development | 2.8yrs | no data | no data | |
| President of Greater China | 2.7yrs | no data | no data | |
| Executive Vice President of Global Clinical Development Vaccines | 2.5yrs | no data | no data | |
| Executive VP & Global Head of Research | 2.3yrs | no data | no data | |
| Head of Global Regulatory Affairs | 2.3yrs | no data | no data |
2.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: 2197's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.2yrs | CN¥5.83m | 16.18% HK$ 52.5m | |
| CEO & Executive Director | 4yrs | CN¥17.39m | 1.6% HK$ 5.2m | |
| Independent Non-Executive Director | 3.3yrs | CN¥3.20m | 0.031% HK$ 101.2k | |
| Non-Executive Director | 2.5yrs | CN¥1.49m | 0.065% HK$ 210.2k | |
| Non-Executive Director | 3.8yrs | CN¥3.18m | 2.19% HK$ 7.1m | |
| Non-Executive Director | 2.5yrs | CN¥907.00k | 0.015% HK$ 48.1k | |
| Independent Non-Executive Director | 3.3yrs | CN¥3.31m | 0.031% HK$ 101.2k | |
| Independent Non-Executive Director | 3.3yrs | CN¥3.28m | 0.031% HK$ 101.2k | |
| Independent Non-Executive Director | 3.3yrs | CN¥3.26m | 0.031% HK$ 101.2k |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: 2197's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clover Biopharmaceuticals, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Credit Suisse |
| Yang Huang | Credit Suisse |
| Ziyi Chen | Goldman Sachs |